Charles River Laboratories International Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
11.3%projected annual EPS growth
Analyst Coverage
14analysts covering
FY EPS (est.)
$11.32next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 4 Nov 2026 |
Monitoring Framework
Key Performance Indicators
DSA Segment Net Book-to-Bill Ratio Quarterly104.0%Target: >= 100x%
Non-GAAP Operating Margin Quarterly1,630.0%Target: 120-150 bps expansion post-divestitures
DSA Segment Backlog Quarterly1.9BTarget: Stable to growing backlog to support >1 year of revenue
Watch Items
- Non-Human Primate (NHP) Supply and Sourcing CostsTrigger: Elevated study-related direct costs or supply delays from CambodiaAction: Accelerate internalization of NHP supply for the DSA segment and optimize global sourcing channels.
- Biotech Funding Environment and Early-Stage SpendingTrigger: High-single digit proposal activity flattening or declining sequentiallyAction: Adjust capacity utilization at discovery sites and focus on customized client-centric approaches under the Pathway to Purpose framework.
- Post-Divestiture Margin AccretionTrigger: Failure to achieve the expected 10 cents per share accretion from CDMO/Cell Solutions saleAction: Implement further cost-saving actions and optimize remaining European discovery service sites.
Research as of 2 Sep 2026